Industry Symposia

These are non-accredited, industry sponsored, Satellite Symposia and are NOT part of the accredited Canadian Breast Cancer Symposium.

Improving Overall Survival in HR+ HER2- mBC: Have We Moved the Needle?

Session time:
Thursday June 13, 1215-1300 hours

Queen’s Quay Room (next to plenary room)

Join top experts for a lively discussion of the current treatment environment in HR+ HER2- mBC.


Dr. Stephen Chia, MD, FRCP(C)
Professor of Medicine, Division of Medical Oncology
University of British Columbia
Medical Oncologist, British Columbia Cancer Agency
Co-chair, Canadian Cancer Trial Group Breast Disease Site
Vancouver, British Columbia

Sunil Verma, MD, MSEd, FRCPC
Head and Professor,
Department of Oncology
Faculty of Medicine,
University of Calgary

Learning Objectives

  • Debate the clinical relevance of the use of various endpoints in mBC trials
  • Review recent data from of CDK 4/6 inhibitors as first-line therapy in mBC
  • Discuss the clinical implications of mechanisms of resistance to CDK 4/6 inhibitors with regard to sequencing strategies
  • Summarize current evidence pertaining to overall survival in patients with HR+ HER2- mBC

This unaccredited event is brought to you by:

My Next Guest Needs No Introduction, with Dr. Stephen Chia
Episode: Views on CDK4/6 Inhibitors and aBC

Session time:
Thursday June 13, 1700-1800 hours

Queen’s Quay Room (next to plenary room)

This symposium will engage clinicians to optimize the management of patients with HR+/HER2- mBC being treated with CDK4/6 inhibitors in order to achieve best clinical outcomes. Presenters include both Canadian and US experts who share their clinical experiences through interview questions and interactive case-based presentations and discussions

Registration Link
Learning Objectives:
After attending this symposium, participants will be better able to:

  • Review the latest evidence and ongoing research in the area of HR+/HER2- metastatic breast cancer to achieve best outcomes for these patients
  • Recognize best practices in the treatment of metastatic breast cancer with CDK4/6 inhibitors through discussions with experts in US and Canada
  • Explore heterogeneity in HR+/HER2- metastatic breast cancer and its implications for treatment choices through case discussions


This unaccredited event is brought to you by

Be it Resolved: Current debates in the role of neo-adjuvant therapy in early breast cancer

Session time:
Friday June 14, 1210-1300 hours

Queen’s Quay Room (next to plenary room)

Chair: Dr. Sunil Verma

  • Dr. Sonal Gandhi (Sunnybrook, Toronto)
  • Dr. Christine Simmons (BC Cancer Agency, Vancouver)
  • Dr. Tulin Cil (UHN, Princess Margaret, Toronto)
  • Dr. Jean-Francois Boileau (Jewish General, Montreal)

Learning Objectives:

  • Evaluate the evidence that supports the use of neoadjuvant therapy in the treatment of breast cancer
  • Outline the remaining gaps in clinical evidence relating to neoadjuvant therapy that still remain
  • Assess how implementing neoadjuvant therapy can impact future treatment decisions

This unaccredited event was brought to you by